pembrolizumab,cue-101
lg chem,pds biotech,merck,cue biopharma
['cue-101', 'keytruda', 'cue-101 ', '$pdsb']
interesting that cue-101 + keytruda in hpv+ and cps &gt; 1 r/m hnscc achieved 42% rr per asco abstract. that is now 3 different techs doubling keytruda rr in unselected tumors via single arm trials in co-positive tumors. is it the t-cell induction or is it the patients? $pdsb